A Randomized, Placebo-Controlled Study in Elderly Alzheimer's Subjects on an Established and Well Tolerated Dose of Aricept to Assess Skin Tolerability, Skin Irritation and Adhesion With Three Consecutive Seven-Day Applications of the 350 mg Donepezil Transdermal Patch-System.

Trial Profile

A Randomized, Placebo-Controlled Study in Elderly Alzheimer's Subjects on an Established and Well Tolerated Dose of Aricept to Assess Skin Tolerability, Skin Irritation and Adhesion With Three Consecutive Seven-Day Applications of the 350 mg Donepezil Transdermal Patch-System.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms (DTP-System
  • Sponsors Teikoku Pharma USA
  • Most Recent Events

    • 26 Apr 2016 Number of treatment arms changed from 1 to 3; study design changed from single group to cross-over assignment.
    • 04 Nov 2011 Additional trial acronym DTP-System identified as reported by ClinicalTrials.gov.
    • 04 Nov 2011 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top